PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2020.138120215341084-1095Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA TrialKyung-Hun Lee, Joohyuk Sohn, Annabel Goodwin, Tiziana Usari, Silvana Lanzalone, Seock-Ah Im, Sung-Bae Kimhttp://e-crt.org/upload/pdf/crt-2020-1381.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2020.1381, http://e-crt.org/upload/pdf/crt-2020-1381.pdf
Annals of Oncology10.1093/annonc/mdz418.001201930ix14Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACAK.-H. Lee, S.-B. Kim, J. Sohn, A. Goodwin, T. Usari, S. Lanzalone, Y.-H. Imhttps://api.elsevier.com/content/article/PII:S0923753419577183?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419577183?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/30/Supplement_9/mdz418.001/31094028/mdz418.001.pdf, http://academic.oup.com/annonc/article-pdf/30/Supplement_9/mdz418.001/31094028/mdz418.001.pdf
Annals of Oncology10.1016/j.annonc.2021.08.552202132S480269P Patient-reported outcomes (PRO) with talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm): Subgroup analysis of pts with and without TALA dose reductions vs PCT in the EMBRACA trialH.S. Rugo, A. Niyazov, H. Bhattacharyya, B. Arondekar, S.A. Hurvitzhttps://api.elsevier.com/content/article/PII:S0923753421027812?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753421027812?httpAccept=text/plain
The Breast10.1016/s0960-9776(19)30743-x201948S71PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS (PTS) WITH HER2− ADVANCED BREAST CANCER (ABC) RECEIVING TALAZOPARIB (TALA) VS PHYSICIAN’S CHOICE CHEMOTHERAPY (PCT): A FOCUS ON EMBRACA GERMLINE BRCA1 AND BRCA2 MUTATION (GBRCA1/2M) SUBGROUPSAnthony Gonçalves, Ruben G.W. Quek, Helen Bhattacharyya, Johannes Ettl, Sara A. Hurvitz, Hope S. Rugohttps://api.elsevier.com/content/article/PII:S096097761930743X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S096097761930743X?httpAccept=text/plain
Annals of Oncology10.1093/annonc/mdz242.052201930v129-v130Patient Reported Outcomes (PRO) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/ without visceral diseaseJ. Ettl, R.G.W. Quek, H. Bhattacharyya, H.S. Rugo, S.A. Hurvitz, A. Gonçalveshttps://api.elsevier.com/content/article/PII:S0923753419585799?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419585799?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz242.052/30083220/mdz242.052.pdf
The Breast10.1016/j.breast.2018.08.080201841S27-S28Patient-reported outcomes (PROs) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA HR+/HER2- subpopulationSara A. Hurvitz, Ruben G.W. Quek, Johannes Ettl, Hope Rugo, Helen Bhattacharyya, Alison L. Hannah, Jennifer Keating Littonhttps://api.elsevier.com/content/article/PII:S0960977618302236?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960977618302236?httpAccept=text/plain
Annals of Oncology10.1093/annonc/mdy272.284201829viii91Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulationH.S. Rugo, R. Quek, J. Ettl, S.A. Hurvitz, H. Bhattacharyya, A.L. Hannah, J.K. Littonhttps://api.elsevier.com/content/article/PII:S0923753419487139?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419487139?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/29/suppl_8/mdy272.284/26139106/mdy272.284.pdf
Annals of Oncology10.1093/annonc/mdy272.295201829viii97Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trialY. Yu, M. Elmeliegy, J.K. Litton, I.C. Tudor, A. Czibere, J. Zheng, D.D. Wanghttps://api.elsevier.com/content/article/PII:S0923753419487243?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419487243?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/29/suppl_8/mdy272.295/26139354/mdy272.295.pdf
Annals of Oncology10.1016/j.annonc.2020.08.2098202031111526-1535Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialJ.K. Litton, S.A. Hurvitz, L.A. Mina, H.S. Rugo, K.-H. Lee, A. Gonçalves, S. Diab, N. Woodward, A. Goodwin, R. Yerushalmi, H. Roché, Y.-H. Im, W. Eiermann, R.G.W. Quek, T. Usari, S. Lanzalone, A. Czibere, J.L. Blum, M. Martin, J. Ettlhttps://api.elsevier.com/content/article/PII:S0923753420421064?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420421064?httpAccept=text/plain
Annals of Oncology10.1093/annonc/mdy25720182991939-1947Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trialJ. Ettl, R.G.W. Quek, K.-H. Lee, H.S. Rugo, S. Hurvitz, A. Gonçalves, L. Fehrenbacher, R. Yerushalmi, L.A. Mina, M. Martin, H. Roché, Y.-H. Im, D. Markova, H. Bhattacharyya, A.L. Hannah, W. Eiermann, J.L. Blum, J.K. Littonhttps://api.elsevier.com/content/article/PII:S0923753419341766?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419341766?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/29/9/1939/25845266/mdy257.pdf